Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Gurkan, Sevgi
- The Use of Bortezomib for Chronic Antibody-mediated Rejection in an Adolescent
Abstract Views :279 |
PDF Views:0
Authors
Affiliations
1 Division of Pediatric Nephrology Robert Wood Johnson Medical School, US
1 Division of Pediatric Nephrology Robert Wood Johnson Medical School, US
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 47-49Abstract
Antibody mediated rejection (AMR) is an important cause of graft failure in kidney transplantation. More recently, the proteasome inhibitor bortezomib has been used in resistant adult AMR cases with promising results. Here we report a kidney transplant patient with chronic AMR who had clinical response to bortezomib treatment after she failed to respond to standard treatment regimes with plasmapheresis and intravenous immunoglobulin (IVIG). Following four weeks of bortezomib treatment, patient's donor specific antibody (DSA) titers declined and her graft function improved. Future studies are needed to determine the clinical efficacy and dosing requirements with bortezomib treatment in pediatric and adult kidney transplant patients with resistant AMR.Keywords
Bortezomib, Rejection, Transplant
References
- Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int 2012;25:623-32.
- Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria - An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14.
- Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibodyand cell-mediated acute rejection. Transplantation 2008;86:1754- 61.
- Flechner SM, Fatica R, Askar M, Stephany BR, Poggio E, Koo A, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010;90:1486-92.
- Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-9.
- Twombley K, Thach L, Ribeiro A, Joseph C, Seikaly M. Acute antibody-mediated rejection in pediatric kidney transplants: A single center experience. Pediatr Transplant 2013; doi: 10.1111/ petr.12129.
- Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012; 93(3): 319-24.
- Waiser J, Budde K, Schutz M, Liefeldt L, Rudolph B, Schonemann C, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012;27: 1246-51.
- Kidney Pathology in Rituximab-Responsive or - Resistant Nephrotic Syndrome Patients
Abstract Views :488 |
PDF Views:0
Authors
Sevgi Gurkan
1,
Lynne Weiss
2
Affiliations
1 Rutgers University-Robert Wood Johnson Medical School, Department of Pediatrics, Division of Pediatric Nephrology, 89 French Street Rm 2209, New Brunswick NJ 08901, US
2 Rutgers, State University of New Jersey, Department of Pediatrics, Division of Pediatric Nephrology, US
1 Rutgers University-Robert Wood Johnson Medical School, Department of Pediatrics, Division of Pediatric Nephrology, 89 French Street Rm 2209, New Brunswick NJ 08901, US
2 Rutgers, State University of New Jersey, Department of Pediatrics, Division of Pediatric Nephrology, US